Cargando…

Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia

The risk factors for eosinophilic pneumonia (EP) remain unclear. We investigate the characteristics of patients with daptomycin (DAP)-induced EP and conducted a retrospective observational study. A total of 450 patients aged ≥ 18 years who received DAP (25 DAP with EP, 425 DAP without EP) were inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Kazuhiro, Matsuo, Takahiro, Tsuda, Yasumasa, Rahman, Mahbubur, Uehara, Yuki, Mori, Nobuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868239/
https://www.ncbi.nlm.nih.gov/pubmed/35203855
http://dx.doi.org/10.3390/antibiotics11020254
_version_ 1784656219165687808
author Ishikawa, Kazuhiro
Matsuo, Takahiro
Tsuda, Yasumasa
Rahman, Mahbubur
Uehara, Yuki
Mori, Nobuyoshi
author_facet Ishikawa, Kazuhiro
Matsuo, Takahiro
Tsuda, Yasumasa
Rahman, Mahbubur
Uehara, Yuki
Mori, Nobuyoshi
author_sort Ishikawa, Kazuhiro
collection PubMed
description The risk factors for eosinophilic pneumonia (EP) remain unclear. We investigate the characteristics of patients with daptomycin (DAP)-induced EP and conducted a retrospective observational study. A total of 450 patients aged ≥ 18 years who received DAP (25 DAP with EP, 425 DAP without EP) were included. The median duration from the first DAP administration to EP onset was 18.0 days. Definite, probable, and possible DAP-induced EP were diagnosed in 0, 9, and 16 patients, respectively. The median age (DAP with EP, 72.0 years; DAP without EP, 64.0 years), DAP dosage/body weight (BW) (9.00 vs. 7.50 mg/kg), blood eosinophil count (cells/μL) (419 vs. 96), and the percentage of hemodialyzed patients (40.0% vs. 13.4%) were significantly higher in patients with EP than in patients without EP in the univariate analysis. In separate multivariate logistic regression analyses, age (odds ratio (OR), 1.03; 95% confidence interval (CI), 1.00–1.05), DAP dosage/BW (OR, 1.61; 95% CI, 1.25–2.07), and hemodialysis (OR, 4.42; 95% CI, 1.86–10.5) were significantly associated with DAP-induced EP. Clinicians may need to consider the potential factors associated with EP, especially in older patients, patients on hemodialysis, or patients who receive > 9.00 mg/kg of DAP.
format Online
Article
Text
id pubmed-8868239
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88682392022-02-25 Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia Ishikawa, Kazuhiro Matsuo, Takahiro Tsuda, Yasumasa Rahman, Mahbubur Uehara, Yuki Mori, Nobuyoshi Antibiotics (Basel) Article The risk factors for eosinophilic pneumonia (EP) remain unclear. We investigate the characteristics of patients with daptomycin (DAP)-induced EP and conducted a retrospective observational study. A total of 450 patients aged ≥ 18 years who received DAP (25 DAP with EP, 425 DAP without EP) were included. The median duration from the first DAP administration to EP onset was 18.0 days. Definite, probable, and possible DAP-induced EP were diagnosed in 0, 9, and 16 patients, respectively. The median age (DAP with EP, 72.0 years; DAP without EP, 64.0 years), DAP dosage/body weight (BW) (9.00 vs. 7.50 mg/kg), blood eosinophil count (cells/μL) (419 vs. 96), and the percentage of hemodialyzed patients (40.0% vs. 13.4%) were significantly higher in patients with EP than in patients without EP in the univariate analysis. In separate multivariate logistic regression analyses, age (odds ratio (OR), 1.03; 95% confidence interval (CI), 1.00–1.05), DAP dosage/BW (OR, 1.61; 95% CI, 1.25–2.07), and hemodialysis (OR, 4.42; 95% CI, 1.86–10.5) were significantly associated with DAP-induced EP. Clinicians may need to consider the potential factors associated with EP, especially in older patients, patients on hemodialysis, or patients who receive > 9.00 mg/kg of DAP. MDPI 2022-02-16 /pmc/articles/PMC8868239/ /pubmed/35203855 http://dx.doi.org/10.3390/antibiotics11020254 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ishikawa, Kazuhiro
Matsuo, Takahiro
Tsuda, Yasumasa
Rahman, Mahbubur
Uehara, Yuki
Mori, Nobuyoshi
Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
title Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
title_full Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
title_fullStr Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
title_full_unstemmed Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
title_short Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
title_sort factors associated with daptomycin-induced eosinophilic pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868239/
https://www.ncbi.nlm.nih.gov/pubmed/35203855
http://dx.doi.org/10.3390/antibiotics11020254
work_keys_str_mv AT ishikawakazuhiro factorsassociatedwithdaptomycininducedeosinophilicpneumonia
AT matsuotakahiro factorsassociatedwithdaptomycininducedeosinophilicpneumonia
AT tsudayasumasa factorsassociatedwithdaptomycininducedeosinophilicpneumonia
AT rahmanmahbubur factorsassociatedwithdaptomycininducedeosinophilicpneumonia
AT ueharayuki factorsassociatedwithdaptomycininducedeosinophilicpneumonia
AT morinobuyoshi factorsassociatedwithdaptomycininducedeosinophilicpneumonia